GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LTS:0A45) » Definitions » Short-Term Debt

Moderna (LTS:0A45) Short-Term Debt : $0 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Moderna Short-Term Debt?

Moderna's Short-Term Debt for the quarter that ended in Dec. 2023 was $0 Mil.

Moderna Short-Term Debt Historical Data

The historical data trend for Moderna's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Short-Term Debt Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial - - - - -

Moderna Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Moderna Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Moderna Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Moderna's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna (LTS:0A45) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LTS:0A45) » Definitions » Short-Term Debt
Comparable Companies
BNTX BGNE ALNY SGEN BMRN RPRX LEGN INCY UTHR SRPT OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 HKSE:02269 XBRU:ARGX SZSE:300122 OCSE:GMAB XKRX:068270
Traded in Other Exchanges
MRNA:USA MRNA:Peru MRNA:Mexico 0QFd:UK 0QF:Germany M1RN34:Brazil MRNA:Austria
Address
200 Technology Square, Cambridge, MA, USA, 02139
Website
https://www.modernatx.com
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna (LTS:0A45) Headlines

No Headlines